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Summary
 
The 24-kD apoptotic protease (AP24) is a serine protease that is activated during apoptosis and
has the capacity to activate internucleosomal DNA fragmentation in isolated nuclei. This study
examined the following: (
 
a
 
) the functional relationship between AP24 and the CPP32-like
proteases of the caspase family; and (
 
b
 
) whether activation of CPP32-like proteases is sufficient
to commit irreversibly a cell to apoptotic death. In three different leukemia cell lines, we
showed that agents that directly (carbobenzoxy-Ala-Ala-borophe (DK120) or indirectly inhibit
activation of AP24 (protein kinase inhibitors, basic fibroblast growth factor, tosylphenylalanine-
chloromethylketone, and caspase inhibitors) protected cells from apoptosis induced by TNF or
UV light. Only the caspase inhibitors, however, prevented activation of CPP32-like activity as
revealed by cleavage of the synthetic substrate, DEVD-pNa, by cell cytosols, and also by in
vivo cleavage of poly (ADP-ribosyl) polymerase, a known substrate of CPP32. Activation of
DEVD-pNa cleaving activity without apoptosis was also demonstrated in two variants derived
from the U937 monocytic leukemia in the absence of exogenous inhibitors. Cell-permeable
peptide inhibitors selective for CPP32-like proteases suppressed AP24 activation and apoptotic
death. These findings indicate that CPP32-like activity is one of several upstream signals re-
quired for AP24 activation. Furthermore, activation of CPP32-like proteases alone is not suffi-
cient to commit irreversibly a cell to apoptotic death under conditions where activation of
AP24 is inhibited.
 
T
 
he process of apoptosis, which normally functions to
maintain homeostasis in cell populations, can be initi-
ated by a variety of stimuli, including withdrawal of growth
factors, various cytokines, ionizing radiation, and cytotoxic
drugs (for review see reference 1). Although these diverse
stimuli initially engage different signal transduction path-
ways, it is postulated that they may converge to activate a
final common death pathway found in all forms of apopto-
sis. In contrast, it is possible that different parallel pathways
are activated by different stimuli that do not overlap from
the initial stimulus to the ultimate death of the cell. The ac-
tual cause of death or the point in the pathway where the
cell is irreversibly committed to die has not yet been estab-
lished.
Intense investigation into the biochemical mechanism of
apoptosis has produced evidence implicating a variety of
enzymes and signal transduction molecules, including pro-
tein kinases and phosphatases, sphingomyelinase (SMase)
 
1
 
,
transglutaminase, ADP ribosyl transferase (ADPRT), and
endonucleases (for review see reference 2). Many recent
studies have focused on the role of proteases that may func-
tion in either signal transduction or as the mediators of ap-
optotic cell death (for review see references 3 and 4). The
best characterized of these proteases is the family of inter-
leukin-1
 
b
 
 converting enzymes (ICE), now called caspases. 
The growing family of ICE-related proteases consists of
at least 10 members that can be divided into 3 subfamilies:
ICE (caspases-1,4,5), CPP32 (caspases-3,6,7,8,10), and Ich-1
(caspases-2,9) (for review see reference 5). All these en-
 
1
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zymes are synthesized as inactive proenzymes that require
cleavage at specific Asp residues to form the active protease.
They require Asp at the P1 site, and based on their sub-
strate specificity, synthetic substrates and inhibitors (with
YVAD specific for the ICE subfamily and DEVD specific
for the CPP32 subfamily) have been designed. Some of
these proteases may autoprocess themselves or other mem-
bers of the family, resulting in a cascade of proteolytic
events that may amplify the initial apoptotic signal. Al-
though the details have yet to be worked out, there is
abundant evidence that some combination of the ICE fam-
ily of proteases is part of a common core death pathway in
apoptosis (reviewed in reference 6).
How the death pathway is engaged after activation of
ICE-related enzymes is not clear (7). Some intracellular
substrates such as poly (ADP-ribosyl) polymerase (PARP)
have been identified that may be involved in cellular repair
mechanisms (8). Whether the cleavage of these substrates is
an irreversible cause of death is not known. Certainly, in-
ternucleosomal DNA cleavage could be considered an irre-
versable lethal event. Certain recombinant proteases such as
CPP32 can cause DNA fragmentation in normal nuclei in
the presence of cell cytosol, but not in the absence of cyto-
sol (9). Thus, there appears to be a missing link between
activation of caspases in the cytosol and the transmission of
apoptotic signals to initiate DNA fragmentation in the nu-
cleus. Evidence generated in our laboratory suggests that
one candidate for this missing link may be AP24, which is
able to activate internucleosomal DNA fragmentation in
normal nuclei in the absence of cytosol (10). AP24 is acti-
vated in and was isolated from the cytosol or nuclei of
U937 cells undergoing apoptosis in response to TNF or
UV light (10). AP24 is a serine protease that binds to and is
inhibited by carbobenzoxy-Ala-Ala-borophe (DK120), a
tripeptide boronic acid–containing inhibitor of chymotrypsin.
In fact, a DK120 affinity resin was used to purify AP24
(10). While efforts are ongoing to clone the cDNA encod-
ing this protease, recent studies have focused on the mech-
anism of activation of AP24 during apoptosis.
Since protein synthesis is not needed for apoptosis in the
U937 model, AP24 must exist in normal cells as an inactive
proenzyme, or else is active but sequestered from its sub-
strate(s). Analysis of signal transduction events leading to
activation of AP24 revealed the participation of several en-
zymes, some of which have been reported in other models
of apoptosis. For example, activation of SMase and produc-
tion of ceramide, which was previously shown to signal ap-
optosis in other systems (11, 12), was found to be an essen-
tial event for AP24 activation by TNF or UV light (13).
ADP ribosylation reaction inhibition has been shown to block
some forms of apoptosis (14–17), and NAD-dependent en-
zymes such as ADPRT are required to signal AP24 activation
(18). Recently, we demonstrated that calcium/calmodulin-
dependent protein kinase II (CaM-KII) is rapidly activated
by TNF or UV light in U937 cells, and that inhibition of
this enzyme prevents AP24 activation and cell death (19, 19a).
A recent report described that a novel form of CaM-K
functions in apoptotic signal transduction (20). These find-
ings at least partially integrate AP24 activation with other
signaling events shown previously to participate in apoptosis.
CPP32 is activated in U937 cells undergoing apoptosis
in response to TNF or ionizing radiation (21). Although
ICE is present in U937 cells and may be constitutively ac-
tive, its activity is not increased by TNF (unlike CPP32
which is proteolytically processed to its active form in apop-
totic U937 cells) (22). These studies examined two ques-
tions: (
 
a
 
) the possible functional relationship between the
CPP32 subfamily and AP24; and (
 
b
 
) whether activation of
CPP32-like proteases by apoptotic stimuli is sufficient to
commit irreversibly a cell to apoptotic death. Our findings
show that activation of CPP32-like proteases is one signal
that contributes to AP24 activation. Activation of the
former protease alone, however, is not sufficient to trigger
apoptotic cell death under circumstances where AP24 acti-
vation is suppressed.
 
Materials and Methods
 
Cell Lines.
 
All cell lines were obtained from the American
Type Culture Collection (Rockville, MD), and were cultured in
RPMI-1640 plus 10% FCS in the absence of antibiotics. All lines
were routinely tested for mycoplasma contamination, and were
always found to be negative. The TNF- and UV light–resistant
U9-TR variant was derived by culturing parental U937 cells in
the presence of TNF, and has been described previously (13, 19).
The NAD-depleted U9-NAD variant was generated by culture
of U937 cells for 2 wk in the absence of nicotinamide, as de-
scribed in detail previously (18).
 
Reagents.
 
KN62 was from Calbiochem Corp. (San Diego,
CA). KT5926 was from Kamiya Biomedical Co. (Thousand
Oaks, CA). Tosylphenylalaninechloromethylketone TPCK), and
the methoxysuccinyl-Ala-Ala-Pro-Val 
 
p
 
-nitroanalide (AAPV-
pNa) substrate were from Sigma Chemical Co. (St. Louis, MO).
DK120 was synthesized by Dr. D.H. Kinder (Ada, OH) as
described previously (23, 24). Cell-permeable Asp-Glu-Val-
Asp-adehyde  (cpDEVD-CHO) was obtained from BIOMOL
Research Labs Inc. (Plymouth Meeting, PA). Side chain fully
methylated carbobenzoxy-Asp-Glu-Val-Asp-chloromethylketone
(DEVD[meth]-cmk), acetyl-Val-Ala-Asp-chloromethylketone
(VAD-cmk), and DEVD-cmk were obtained from Panorama Re-
search (Mountain View, CA). Human recombinant bFGF was
obtained from R&D Systems (Minneapolis, MN).
 
Measurement of DNA Fragmentation and Percent of Apoptotic
Cells.
 
To induce apoptosis, U937 cells were exposed to UV light
in a Stratalinker
 
Ô
 
 or to TNF plus cycloheximide 0.5 
 
m
 
g/ml. Per-
cent DNA fragmentation was determined by measuring release of
 
3
 
H-labeled DNA fragments as described in detail previously (17).
In some experiments the percent of morphologically apoptotic
cells was enumerated microscopically as described previously (17).
Morphologically apoptotic cells were defined as those exhibiting
at least two or more prominent membrane protuberances. This
change occurs before cell death (defined as the inability to ex-
clude trypan blue). The kinetics of appearance of morphologically
apoptotic cells correlates with DNA fragmentation as previously
documented (17).
In every experiment that cells were exposed to the various in-
hibitors, controls were examined microscopically at the end of 
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the assay to verify that all inhibitors were used at nontoxic con-
centrations.
 
Assay of DEVD-pNa Cleavage.
 
CPP32-like activity was mea-
sured in the cytosol of cells treated with various inhibitors and in-
ducers of apoptosis. Cells were lysed at a density of 2 
 
3
 
 10
 
6
 
/ml in
50 mM Tris, pH 7.5, 0.03% NP-40, 1.0 mM DTT. Assays were
set up in flat-bottomed 96-well plates containing 0.2 mM
DEVD-pNa in PBS, and 0.01 ml of cytosol in a total volume of
0.1 ml. Assays were incubated at 37
 
8
 
C with periodic readings of
OD at 405 nm taken from 0–3 h. Specific activity was calculated
as the amount of enzyme that hydrolyzes 1 nmol substrate/h per
mg total protein.
 
Partial Purification and Quantitation of AP24 Activity.
 
Proteolytic
activity of AP24 was quantitated as described in detail previously
(18). In brief, cells were incubated with or without inducing
agents for 1.5 h, and lysates were prepared, from which AP24 was
purified by affinity chromatography using DK120 as ligand. Total
units of AP24 proteolytic activity eluted from the column were
quantitated using the AAPV-pNa substrate (18). In some experi-
ments, AP24 activity was quantitated using the nuclear DNA
fragmentation assay described below. In this case, AP24 units
were defined as the reciprocal of the dilution of affinity-purified
enzyme required to mediate 30% DNA fragmentation in isolated
nuclei.
 
Assay of DNA Fragmentation in Isolated Nuclei.
 
DNA fragmen-
tation in isolated nuclei was assayed as described in detail previ-
ously (10). [
 
3
 
H]thymidine-labeled U937 cells were pelleted, and
the cytoplasmic membrane was lysed by resuspending the cells in
assay buffer (50 mM Tris, pH 7.5, 250 mM sucrose, 10 mM
MgSO
 
4
 
) plus 0.02% NP-40. Nuclei were then pelleted and resus-
pended in assay buffer at 1 
 
3
 
 10
 
6
 
/ml. The assay was set up in
triplicate in flat-bottomed microtiter plates under sterile condi-
tions. Nuclei (0.05 ml) were mixed with 0.05 ml of sample di-
luted in 50 mM Tris, pH 7.5, or buffer alone, to determine total
counts. Plates were incubated for 5 h at 37
 
8
 
C, and were then har-
vested by adding 0.1 ml of harvesting buffer (10 mM Tris, pH
7.5, 10 mM EDTA, 0.3% Triton X-100). High molecular weight
DNA was collected by filtration onto glass fiber paper, and the ra-
dioactivity was counted on a Matrix 96 
 
b
 
 counter (Packard Instrs.,
Meriden, CT). Percent DNA fragmentation was calculated as fol-
lows: ([total cpm 
 
2 
 
test cpm]/total cpm) 
 
3
 
 100. The spontane-
ous release of [
 
3
 
H]thymidine relative to the total counts at the ini-
tiation of the assay did not exceed 5%.
In some experiments, nuclei were further purified by centrifu-
gation through a cushion of 30% sucrose, and were compared to
nuclei isolated as above. We found that both preparations of nu-
clei were equally sensitive to DNA fragmentation induced by af-
finity-purified AP24 (unpublished observations). This finding ar-
gues against the possibility that contamination of the nuclei by
cytosol components is required for the AP24 capacity to induce
nuclear DNA fragmentation.
 
Immunoblot Analysis.
 
For PARP detection, 8 
 
3
 
 10
 
4
 
 cells
were lysed in sample buffer (62.5 mM Tris/HCl, pH 6.8, 6 M
urea, 10% glycerol, 2% SDS, and 0.00125% bromophenol blue),
electrophoresed in 10% denaturing polyacrylamide gels, and then
transferred to Immobilon-P blotting membrane (Millipore Corp.,
Bedford, MA). The membranes were incubated with rabbit poly-
clonal antibody against PARP (BIOMOL) at a 1/2,500 dilution.
This incubation was followed by incubation with biotinylated
goat anti–rabbit IgG (1/3000; GIBCO BRL, Gaithersburg, MD).
After reaction with strepavidin-alkaline phosphatase conjugate
(1/3,000; GIBCO BRL), the blots were developed with Sigma-
Fast BCIP/NBT solution as recommended by the vendor (Sigma
Chemical Co.).
 
Results
 
Agents That Inhibit Apoptosis Do Not Necessarily Prevent
Activation of CPP32-like Activity.
 
Our studies on the mech-
anism of apoptosis have identified a variety of compounds
that inhibit TNF or UV light–induced apoptosis in U937
cells. Since CPP32 has been shown to be activated as an es-
sential step in TNF (22) or ionizing radiation (21)–induced
apoptosis in U937 cells, experiments were performed to
determine if these apoptosis inhibitors block activation of
CPP32-like enzymes. In preliminary experiments, we veri-
fied that CPP32-like activity was indeed increased by treat-
ment with TNF or UV light in U937 cells, as measured on
the synthetic substrate, DEVD-pNa. Kinetic studies re-
vealed that the peak of DEVD-pNa cleaving activity in
U937 cytosol extracts is found 60–90 min after exposure to
either TNF or UV light (data not shown). Therefore, in
the following experiments, U937 cells were pretreated for
1 h with various inhibitors, exposed to TNF or UV light,
and incubated at 37
 
8
 
C for 60 min. Cytosol extracts were
assayed for proteolytic activity on the DEVD-pNa sub-
strate. Aliquots of cells treated identically were incubated
for 1.5 h, and then the percentage of morphologically apop-
totic cells were enumerated microscopically. Our previous
studies showed that the development of apoptotic mor-
phology coincides with DNA fragmentation, which precedes
cell death (measured by trypan blue exclusion) by about 1 h
(17). Two serine protease inhibitors, TPCK and DK120,
which we previously reported to block apoptotic DNA
fragmentation (10), did not prevent TNF or UV light acti-
vation of DEVD-pNa cleaving activity, even at concentra-
tions that completely prevented apoptosis (Table 1, experi-
ment 1). In contrast, the broad spectrum inhibitor of the
ICE family, VAD-cmk, completely prevented activation of
DEVD-pNa cleaving activity, and also inhibited apoptosis,
as expected (experiments 2 and 4). Other agents tested in-
cluded two mechanistically different inhibitors of CaM-KII,
KN62 (25) and KT5926 (26), both of which suppressed apo-
ptosis (Table 1, 19, 19a) but had no significant effect on
UV light activation of DEVD-cleaving activity (experi-
ments 2 and 3). We also found that bFGF protected cells
from apoptosis without blocking activation of CPP32-like
proteases (experiment 4). All the inhibitors also suppressed
DNA fragmentation, measured by release of 
 
3
 
H-labeled
DNA fragments at 1.5 h (data not shown). These results in-
dicate that activation of CPP32-like proteolytic activity is
not sufficient to induce apoptosis within the time frame ex-
amined. This is not unique to U937 cells, since we found
that DK120 and TPCK could also inhibit apoptosis in the
CEM T cell leukemia and the HL-60 myeloid leukemia
without preventing UV light activation of DEVD-pNa–
cleaving activity (Table 2).
To confirm the results obtained with the synthetic sub-
strate, we also examined the effects of the apoptosis inhibi- 
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tors on in vivo cleavage of PARP, a known substrate of
CPP32, in apoptotic U937 cells. U937 cells were pre-
treated for 1 h with the inhibitors, followed by exposure to
either UV light or TNF. After incubation for 1.5 h, the
percentage of apoptotic cells was enumerated microscopi-
cally, and cell lysates were analyzed by Western blotting
with antibody directed against PARP. As expected, in cells
exposed to UV light, and to a somewhat lesser extent,
TNF, PARP was cleaved to an 85-kD fragment (Fig. 1).
Three inhibitors, bFGF, KT5926, and DK120, did not
prevent cleavage of PARP in response to either TNF or
UV light, although they almost completely prevented the
appearance of apoptotic cells. In contrast, VAD-cmk com-
pletely prevented PARP cleavage, and also protected from
apoptosis, as expected. These findings demonstrate that
some agents that inhibit apoptosis do not block intracellular
cleavage of PARP. These inhibitors may be acting at a site
downstream of CPP32-like activity, or else on a separate
parallel pathway that is independent of DEVD-pNa cleav-
ing activity.
Do the protective inhibitors that suppress AP24 activa-
tion actually prevent apoptosis, or do they just delay it?
This cannot be tested directly since most of the inhibitors
alone except for bFGF are toxic to cells upon long-term
exposure. In a 24-h experiment, we found that all of the
cells exposed to TNF or UV light had died, with high lev-
els of DNA fragmentation (Table 3). Approximately 50%
of cells pretreated with bFGF followed by TNF or UV
light survived at 24 h, and appeared morphologically nor-
mal. Almost 50% of the bFGF-treated cells exposed to
TNF or UV light, however, died a necrotic death as evi-
denced by trypan blue uptake in the absence of DNA frag-
 
Table 1.
 
Inhibition of Apoptosis by Agents That Do Not Prevent Activation of CPP32-like Activity in U937 Cells
 
Experiment Cell treatment
 
*
 
Apoptotic
cells
DEVD-pNa
cleaving activity
 
% nmol/h/mg
 
1— 0 0
TNF 2 ng/ml 46 12.8
TNF 
 
1
 
 DK120 2 
 
m
 
M 0 13.1
TNF 
 
1
 
 DK120 1 
 
m
 
M 29 13.9
TNF 
 
1
 
 TPCK 2 
 
m
 
M 0 9.9
TNF 
 
1
 
 TPCK 1 
 
m
 
M 30 9.5
UV light 0.06 J/cm
 
2
 
64 16.8
UV light 
 
1
 
 DK120 2 
 
m
 
M 0 12.6
UV light 
 
1
 
 DK120 1 
 
m
 
M 40 12.9
UV light 
 
1
 
 TPCK 2 
 
m
 
M 0 19.0
UV light 
 
1
 
 TPCK 1 
 
m
 
M 38 15.3
2 — 0 3.9
UV light 0.06 J/cm
 
2
 
58 63.3
UV light 
 
1 
 
VAD-cmk 2 
 
m
 
M 12 2.0
UV light 
 
1
 
 DK120 2 
 
m
 
M 15 59.1
UV light 
 
1
 
 TPCK 2 
 
m
 
M 15 79.9
UV light 
 
1
 
 KN62 20 
 
m
 
M 11 70.8
3 — 0 3.5
UV light 0.06 J/cm
 
2
 
59 80.4
UV light 
 
1 
 
KT5926 5 
 
m
 
M 0 76.2
4 — 0 2.4
TNF 2 ng/ml 46 8.8
TNF 
 
1
 
 VAD-cmk 5 
 
m
 
M 0 1.4
TNF 
 
1
 
 bFGF 1.0 ng/ml 0 6.3
UV light 0.06 J/cm
 
2
 
68 13.1
UV light 
 
1 
 
VAD-cmk 5 
 
m
 
M0 0
UV light 
 
1
 
 DK120 5 
 
m
 
M 0 10.5
UV light 
 
1
 
 bFGF 1.0 
 
m
 
M 0 17.6
 
*
 
U937 cells were pretreated for 1 h with the inhibitors, except for bFGF, which was pretreated 3 h. After exposure to TNF or UV light, cells were
incubated 1.5 h to determine percent apoptotic cells, and 1 h to measure cleavage of DEVD-pNa by the cytosol. 
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mentation. Therefore, bFGF prevented apoptosis in all of
the cells, and conferred 24-h survival in 
 
z
 
50% of the cells
(as opposed to 0% survival in cells without bFGF). The fact
that half the bFGF-treated cells still died indicates that apop-
totic stimuli may also activate a delayed mechanistically dif-
ferent necrotic death that is at least partially resistant to pro-
tection by bFGF.
 
U937 Variants are Resistant to UV Light-induced Apoptosis,
Although They Still Show Normal Activation of DEVD-cleaving
Activity.
 
Since the above studies all used exogenous in-
hibitors to prevent apoptosis while leaving DEVD-cleaving
activity intact, it was of interest to determine if this phe-
nomenon can ever be observed in the absence of exoge-
nous inhibitors. We previously described two variants de-
rived from U937 that are both relatively resistant to
apoptosis induced by either TNF or UV light. The U9-TR
variant was generated by the prolonged culture of parental
U937 cells in the presence of TNF (19), and the U9-NAD
variant (18) was produced by nutritional depletion of nico-
tinamide, the biosynthetic precursor of NAD. Both of
these variants responded normally to UV light–induced ac-
tivation of CPP32-like protease activity with kinetics simi-
lar to that of normal U937 cells (Fig. 2 
 
A
 
). In contrast, both
of the variants were almost completely resistant to apoptosis
(Fig. 2 
 
B
 
), in agreement with previous findings (18, 19).
Similar results were obtained when apoptosis was activated
by TNF (data not shown). Although we usually incubate
U937 cells for 1.5–2 h to measure morphological apoptotic
changes as well as DNA fragmentation, cell death does not
occur until later time points. In this experiment, 6 h after
exposure to UV light, 51% of U937 cells were dead, ac-
cording to trypan blue exclusion, whereas both variants
were still 
 
.
 
95% viable. This experiment provides further
evidence that activation of CPP32-like proteases is not suf-
ficient to lead to apoptosis, even in the absence of exoge-
nous inhibitors.
 
Cell-permeable Peptide Inhibitors of CPP32 Prevent TNF or
UV Light Activation of DEVD-pNa Cleaving Activity and Ap-
optosis.
 
The above findings led us to question whether ac-
tivation of CPP32-like proteases is, in fact, essential for ap-
optosis in this system. In preliminary experiments, we
found that apoptosis of U937 is quite refractory to inhibi-
tion by conventional tetrapeptide inhibitors of CPP32
(e.g., DEVD-CHO), even up to 500 
 
m
 
M. This finding is
in agreement with another report (27), and is probably due
 
Table 2.
 
Inhibition of Apoptosis by Agents That Do Not Prevent 
Activation of CPP32-like Activity in CEM and HL-60 Cells
 
Cell
line Cell treatment
 
*
 
Apoptotic
cells
DEVD-pNa
cleaving activity
 
% nmol/h/mg
 
CEM — 0 22
CEM UV light 0.06 J/cm
 
2
 
48 83
CEM UV light 
 
1 
 
VAD-cmk 2 
 
m
 
M 31 9.2
CEM UV light 
 
1
 
 DK120 2
 
m
 
M1 8 5 3
CEM UV light 
 
1 
 
TPCK 2 
 
mM8 5 6
HL-60 — 0 15
HL-60 UV light 0.06 J/cm2 51 27
HL-60 UV light 1 VAD-cmk 2 mM 29 5.4
HL-60 UV light 1 DK120 2 mM1 6 4 1
HL-60 UV light 1 TPCK 2 mM9 2 6
* Cells were pretreated for 1 h with the inhibitors. After exposure to
UV light, cells were incubated 1.5 h to determine percent apoptotic
cells and 1 h to measure cleavage of DEVD-pNa by the cytosol.
Figure 1. Some inhibitors of
apoptosis do not prevent cleav-
age of PARP. U937 cells were
pretreated for 1 h with the indi-
cated inhibitors, exposed to TNF
or UV light, and incubated for
1.5 h. Cell lysates were analyzed
for PARP by immunoblotting.
Table 3. bFGF Prevents Apoptotic Death and Partially Protects 
from Necrosis 24 h after Exposure to Apoptosis Inducers
Cell treatment* Viability
DNA
fragmentation
%%
TNF 2 ng/ml 0 86 6 6.5
TNF 1 bFGF 2 ng/ml 58 0
UV light 0.06 J/cm2 0 78 6 7.0
UV light 1 bFGF 2 ng/ml 50 0
*U937 cells were pretreated 3 h with bFGF before exposure to TNF or
UV light. 24 h later, viability was determined by trypan blue exclusion
and DNA fragmentation was measured by release of 3H-labeled DNA
fragments.1112 Inhibition of AP24 Suppresses Apoptosis Even Though CPP32 Is Activated
to the poor membrane permeability of these tetrapeptide
inhibitors. Therefore, we tested the novel inhibitor, cp-
DEVD-CHO, that was rendered cell permeable by attach-
ment of a signal peptide, as described (28). cpDEVD-CHO
inhibited both intracellular activation of CPP32-like activ-
ity, as well as apoptosis and DNA fragmentation at concen-
trations ranging from 0.25–1.0 mM (Table 4). Another
modification that increases inhibitor permeability is methy-
lation on side chain carboxyl groups, and such a com-
pound, DEVD(meth)-cmk, also inhibited activation of
CPP32-like activity as well as apoptosis at concentrations
ranging from 2.5–10.0 mM (Table 4). It should be noted
that after treatment of cells with inhibitors, followed by ex-
posure to the apoptosis inducer and incubation for 1 h, the
cells were washed before lysing, to remove extracellular in-
hibitor. Therefore, the decreased DEVD-pNa cleaving ac-
tivity of the cytosol must be due to penetration of the in-
hibitor into the intact cell, as opposed to contamination of
the cytosol with extracellular inhibitor after the cell is lysed.
The cytosols were assayed immediately after cell lysis. Al-
though aldehyde inhibitors are slowly reversible, the inhib-
itory effect of cpDEVD-CHO was still readily apparent
during the time frame of this assay (1–2 h). These data sup-
port the conclusion that activation of CPP32 and/or similar
proteases is essential for TNF or UV light–induced apopto-
sis of U937 cells. Therefore, inhibitors that block apoptosis,
but not activation of DEVD-pNa cleaving activity, must
either act downstream of CPP32-like proteases, or else on a
separate signal transduction pathway.
All Agents Tested That Inhibit Apoptosis Suppress Activation
of AP24, Regardless of Whether They Inhibit Activation of
CPP32-like Proteases. To further explore the mechanism
of protection from apoptosis by the agents in Table 1, we
tested the effects of these agents on activation of AP24 in
apoptotic cells. U937 cells were pretreated with the various
inhibitors, exposed to TNF or UV light, and incubated for
1.5 h, at which point the percentage of apoptotic cells was
determined, and cytosol extracts were prepared. AP24 was
purified from the cytosol by chromatography on DK120
affinity columns as described in Materials and Methods.
AP24 activity was quantitated using a synthetic substrate,
and in some experiments, by measuring induction of DNA
fragmentation in isolated normal nuclei. As noted previ-
ously (10), we always find some AP24 activity in cytosols
from normal cells which may be due to the presence of low
numbers of apoptotic cells in culture, or else to the artifac-
tual activation of AP24 during purification. Cells undergo-
ing apoptosis, however, always show a significant increase
in active AP24 purified from their cytosol. As shown in Ta-
ble 5 experiment 1, cpDEVD-CHO inhibited TNF-induced
activation of AP24 as measured on a synthetic substrate, as
well as activation of DNA fragmentation in isolated nuclei.
DK120 also inhibited AP24, as shown previously. Experi-
ment 2 shows that VAD-cmk attenuated TNF activation of
AP24, and partially suppressed apoptosis, thus supporting
the results with cpDEVD-CHO. These results indicate that
a CPP32-like protease provides at least one signal leading
to activation of AP24. Experiments 3–5 in Table 5 show
that treatment with TPCK, bFGF, or KT5926 all attenu-
ated TNF or UV light activation of AP24. Therefore, all
agents tested that inhibit apoptosis also suppressed activa-
tion of AP24, even though some of them still allowed acti-
vation of CPP32-like proteases.
Specificity of Protease Inhibitors Used in This Study. Both the
broad spectrum inhibitor of the ICE family, VAD-cmk,
and the selective inhibitor of the CPP32 subfamily,
DEVD-CHO, potently inhibited DEVD-pNa cleaving ac-
tivity in the cytosol from apoptotic cells (Table 6). It should
be noted that the cell-permeable inhibitor cpDEVD-CHO
was just as active in vitro as was the unmodified tetrapep-
tide inhibitor. In contrast, the two chymotrypsin inhibitors,
DK120 and TPCK, were inactive at 20 mM. This result
shows that the AP24 inhibitor, DK120, does not crossreact
with CPP32-like proteases found in apoptotic U937 cyto-
sol at concentrations used in this study. Furthermore, only
DK120, and not DEVD-CHO or VAD-cmk, inhibited
AP24 induction of nuclear DNA fragmentation, confirm-
ing that this protease is probably not related to the caspase
family.
Discussion
Of all the caspases studied thus far, most of the evidence
favors a role for CPP32 and/or other members of this sub-
Figure 2. Activation of CPP32-like proteases in normal and resistant
U937 variants. (A) Normal U937 cells, TNF-selected variants (U9-TR),
and NAD-depleted variants (U9-NAD) were exposed to UV light 0.06
J/cm2, incubated for the indicated time, and cytosol extracts were assayed
for proteolytic activity on the DEVD-pNa substrate. (B) U937 and the
variants were incubated for 90 min after exposure to UV light, and the
morphologically apoptotic cells were enumerated microscopically.1113 Wright et al.
family in the mechanism of apoptosis. One issue that has
not been previously addressed is whether activation of
CPP32-like activity is sufficient to commit a cell to apop-
tosis in response to various stimuli. Although overexpres-
sion of each of the members of the ICE family has been
shown to induce apoptosis (6), this is not convincing evi-
dence that activation of these enzymes will irreversibly
commit a cell to apoptosis. These effects could be nonspe-
cific, since introduction of high concentrations of proteases
such as trypsin or chymotrypsin into the cytosol will also
induce apoptosis (29). Clearly, activation of ICE can occur
in monocytes engaged in the production of Il-1b in the ab-
sence of apoptotic death (30). However, a similar example
of TNF or UV light activation of CPP32-like activity in
the absence of apoptosis has not been reported. Thus, it is
possible that activation of CPP32-like proteases is an irre-
versible step in the apoptotic pathway.
These studies took a different approach to evaluate the
role of CPP32-like enzymes by asking whether apoptotic
death could be prevented in cells that still showed full acti-
vation of DEVD-pNa cleaving activity in response to apop-
totic stimuli. Treatment with various agents was shown to
protect several leukemia cell lines from apoptosis induced
by TNF or UV light. None of these treatments (with the
exception of the caspase inhibitors), however, prevented
activation of CPP32-like proteases as revealed by cleavage
of the DEVD-pNa substrate by the cell extracts. The lack
of inhibition of CPP32 was confirmed in intact cells by
demonstration of the cleavage of PARP to its characteristic
85-kD fragment.
This phenomenon was also observed in the absence of
exogenous inhibitors in the case of the U9-TR and NAD-
depleted U937 variants. These cells showed UV light acti-
vation of DEVD-pNa cleaving activity with kinetics and
magnitude identical to parental U937. Both of these variants,
however, were highly resistant to TNF or UV light–induced
apoptosis, and have a defect in the signaling pathway lead-
ing to activation of AP24, as shown in our previous studies
(13, 18). U9-TR has a defect in signals leading to SMase
activation (13), whereas NAD-depleted U937 variants ap-
pear to be resistant due to a lack of ADP-ribosylation reac-
tions (18). According to our model, both ADPRT and
SMase function upstream of activation of AP24 in the apop-
totic pathway. The results with the variants show that even in
the absence of exogenous inhibitors, cells may avoid apop-
totic death, despite the fact that CPP32-like proteases have
been activated.
This investigation also examined the morphological
changes that accompany apoptosis as observed by light mi-
croscopy, which include formation of protrusions of the
cell membrane, and budding of apoptotic bodies. Inhibitors
that prevented apoptosis also blocked these morphological
changes, even though CPP32-like proteases were still acti-
vated. Likewise, the two resistant variants did not undergo
the morphological alterations of apoptosis. Therefore, acti-
vation of CPP32-like proteases alone is not sufficient to
cause these morphological changes associated with apoptosis.
This raised the question of whether activation of CPP32-
like proteases is necessary, or is just an epiphenomenon in
this model of apoptosis. Inhibition of DNA fragmentation
Table 4. Inhibition of Activation of CPP32-like Protease and Apoptosis by Cell-permeable CPP32 Inhibitors
Cell treatment*
Apoptotic
cells
DEVD-pNa 
cleaving activity
DNA
fragmentation
% nmol/h/mg %
— 0 9.5 0
TNF 2.0 ng/ml 41 78.8 48 6 4.8
TNF 1 cpDEVD-CHO 1.0 mM 8 1.1 0
TNF 1 cpDEVD-CHO 0.5 mM 11 38.6 21 6 0.8
TNF 1 cpDEVD-CHO 0.25 mM 20 46.5 ND
TNF 1 cpDEVD-CHO 0.125 mM 31 80.5 ND
—0 0 0
UV light 0.06 J/cm2 58 20.4 53 6 4.2
UV light 1 cpDEVD-CHO 1.0 mM 11 3.4 12 6 0.6
UV light 1 cpDEVD-CHO 0.25 mM 38 8.8 ND
— 0 3.5 0
UV light 0.06 J/cm2 59 80.4 46 6 4.6
UV light 1 DEVD(meth)-cmk 10 mM 8 12.2 0
UV light 1 DEVD(meth)-cmk 5 mM 18 27.8 0
UV light 1 DEVD(meth)-cmk 2.5 mM 39 46.6 15 6 4.5
*U937 cells were pretreated with inhibitors for 2 h before exposure to TNF or UV light. After 1 h of incubation, cells were pelleted, washed twice
in PBS, and lysed to measure protease activity on the DEVD–pNa substrate. The percent morphologically apoptotic cells and percent DNA frag-
mentation was determined after 1.5 h incubation. ND, not determined.1114 Inhibition of AP24 Suppresses Apoptosis Even Though CPP32 Is Activated
by low micromolar concentrations of cell-permeable pep-
tide inhibitors of CPP32 (cpDEVD-CHO and DEVD
(meth)-cmk), however, indicates that this subfamily of pro-
teases is needed for optimal apoptotic signal transduction.
Therefore, we hypothesize that the protective agents that
do not inhibit CPP32 must be blocking events that occur
downstream of this protease, or else they interfere with a
separate parallel signal transduction pathway that is inde-
pendent of CPP32.
How do the protective inhibitors prevent apoptosis if
they do not block activation of CPP32? Although the
mechanism of action of these inhibitors is not fully under-
stood, one property they have in common is the direct
(DK120) inhibition of AP24 proteolytic activity, or the
suppression of activation of intracellular AP24 by apoptotic
stimuli (KT5926, TPCK, and bFGF). KT5926 (26) and
KN62 (25) are two selective and mechanistically different
inhibitors of CaM-KII. Our previous work demonstrated
that both TNF and UV light rapidly activated CaM-KII in
U937 cells (19a). Furthermore, inhibitors of this kinase
blocked activation of AP24 and apoptotic death (19). TPCK
is a chymotrypsin inhibitor that may have multiple sites of
action, however, our evidence suggests that it blocks sig-
naling events leading to activation of AP24. It is not clear
how bFGF inhibits activation of AP24, however, one pos-
sibility is through activation of protein kinase C (PKC), a
mechanism previously proposed for bFGF inhibition of ap-
optosis (31). Indeed, we have shown that brief pretreat-
ment with phorbol myristate acetate, which activates PKC,
will inhibit TNF or UV light–induced apoptosis in U937
cells (unpublished observations). Further work is in progress
to analyze the mechanism by which bFGF inhibits activa-
tion of AP24.
The capacity of AP24 to induce internucleosomal DNA
fragmentation in isolated nuclei distinguishes it from several
other proteases that cleave at aspartic acid residues, such as
Granzyme B (32), ICE (33), and CPP32 (9). Unlike AP24,
all these enzymes require the presence of cytosolic compo-
nents to activate nuclear DNA fragmentation in cell-free
systems. We hypothesize that AP24 may play a key role in
transmitting apoptotic signals from the cytosol to the nu-
cleus, where it directly or indirectly activates endogenous
endonucleases resulting in DNA digestion. We cannot,
however, rule out the possible existence of cytosolic sub-
strates of AP24, since high levels of this protease were orig-
inally detected in apoptotic cytosol (10), and purified AP24
can cleave several cytoskeleton-associated proteins in vitro
(our unpublished observations).
Until recently, AP24 was the only protease reported to
cause DNA fragmentation in isolated nuclei. Now, another
Table 5. Inhibition of Activation of AP24 by Agents That Suppress Apoptosis
Experiment Cell treatment* AP24‡
AP24 nuclear
activity
Apoptotic
cells
nmol/mg/h U/ml %
1 — 362 ,2N D
TNF 2 ng/ml 1395 8 ND
TNF 1 cpDEVD-CHO 2 mM 777 2 ND
TNF 1 DK120 5 mM 805 3 ND
2 — 139 ND 0
TNF 5 ng/ml 722 ND 48
TNF 1 VAD-cmk 2.5 mM 389 ND 29
3 — 494 ,20
UV light 0.06 J/cm2 947 8 48
UV light 1 TPCK 2 mM 606 ,20
4 — 632 ND 0
TNF 2 ng/ml 1554 ND 48
TNF 1 bFGF 2 ng/ml 996 ND 11
5 — 108 ND 1
TNF 5 ng/ml 348 ND 56
TNF 1 KT5926 5 mM 126 ND 6
UV light 0.08 J/cm2 352 ND 67
UV light 1 KT5926 5 mM 128 ND 8
*Cells were pretreated with inhibitors for 1 h except for cpDEVD-CHO and bFGF, which were pretreated for 3 h before exposure to TNF or UV
light. ‡AP24 activity was quantitated using the AAPV-pNa substrate or the nuclear assay after purification of cell lysates on DK120 affinity columns
as described in Materials and Methods. ND, not determined.1115 Wright et al.
factor with similar activity has been partially characterized
as a 50-kD protein released from mitochondria, whose ac-
tivity on isolated nuclei is inhibited by VAD-fmk (34).
Whether this protein is a new member of the ICE family
has not been clarified, however, it is clearly different from
AP24 with respect to molecular weight and susceptibility
to protease inhibitors.
Another protein recently reported to activate DNA frag-
mentation in nuclei was isolated from HeLa cell cytosol, al-
though it was not reported to be a protease (35). Interest-
ingly, this protein, called DFF, exists as a precursor that is
proteolytically activated by CPP32. The possible relation-
ship between AP24 and DFF, or its activated fragments, is
currently under investigation.
Recent findings in a different model of apoptosis indi-
cate that overexpression of Bcl-xL will prevent anti-Fas-
induced death of Jurkat cells without preventing activation
of ICE-like proteases (36). One possible interpretation is
that high levels of Bcl-xL act downstream of ICE-like pro-
teases to prevent mitochondrial permeability transition,
which has been proposed as an irreversible step in apoptosis
(37). Alternatively, in a process that is blocked by overex-
pression of Bcl-2, mitochondria can release cytochrome c,
which then promotes activation of CPP32 before the per-
meability transition (38, 39). If this model is correct, then
AP24 activation may occur downstream of cytochrome c
release and CPP32 activation. Studies are currently under-
way to examine the possible relationship between mito-
chondrial function and AP24 activation.
A recent report indicates that CPP32 is activated during
PHA stimulation of T lymphocytes in the absence of apop-
tosis (40). This finding, as well as our results, suggest that
CPP32 may have additional physiological functions that are
unrelated to apoptosis.
The evidence that activation of DEVD-pNa cleavage
does not irreversibly commit a cell to apoptosis, as well as
the finding that activation of AP24 occurs downstream of
CPP32-like activity, has important therapeutic implica-
tions. Inappropriate apoptosis contributes to the pathology
of a variety of conditions (reviewed in 41). Inhibitors that
block apoptosis may attenuate tissue damage, provided that
subsequent necrosis does not negate the beneficial effects.
Recently there has been considerable interest in the devel-
opment of therapeutic inhibitors of ICE-related proteases
to treat conditions involving inappropriate apoptosis (42).
Apoptosis has been reported to be at least one component
of cell death resulting from ischemia reperfusion injury in
conditions such as neuronal stroke (43) and in heart failure
(44, 45). Activation of CPP32 has been reported in cardiac
myocytes of heart patients (46), and ICE was activated in
an animal model of neuronal ischemia reperfusion injury
(47). Furthermore, neuronal damage was ameliorated by
administration of peptide inhibitors of ICE or CPP32, al-
though there was a very short therapeutic window (,1 h)
after reperfusion (47). In victims of acute ischemia reperfu-
sion injury, cells may have received apoptotic signals hours
before medical treatment is available. In these situations,
drugs that block early apoptotic signaling events may not
be useful. Since AP24 appears to function downstream of
CPP32-like proteases, inhibition of AP24 may represent a
superior therapeutic approach for treatment of acute apop-
totic cell injury.
Table 6. Specificity of Protease Inhibitors. Effects on CPP32-like 
Activity and on Nuclear DNA Fragmenting Activity by AP24
Assay Inhibitor IC50
mM
Cleavage of DEVDpNa byUV light-
activated cytosol cpDEVD-CHO 0.009
Cleavage of DEVDpNa by UV light-
activated cytosol DEVD-CHO 0.007
Cleavage of DEVDpNa by UV light-
activated cytosol VAD-cmk 0.010
Cleavage of DEVDpNa by UV light-
activated cytosol DK120 .20.0
Cleavage of DEVDpNa by UV light- 
activated cytosol TPCK .20.0
DNA fragmentation in U937 nuclei
by AP24 DEVD-CHO .20.0
DNA fragmentation in U937 nuclei
by AP24 VAD-cmk .20.0
DNA fragmentation in U937 nuclei
by AP24 DK120 0.016
DNA fragmentation in U937 nuclei
by AP24 TPCK .20.0
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